2. Search Result
Search Result
Results for "

plaque psoriasis

" in MedChemExpress (MCE) Product Catalog:

23

Inhibitors & Agonists

9

Inhibitory Antibodies

2

Natural
Products

4

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P9925
    Brodalumab
    2 Publications Verification

    AMG 827; KHK4827

    		 Interleukin Related Inflammation/Immunology
    Brodalumab (AMG 827) is a human anti-interleukin-17-receptor IgG2 monoclonal antibody that can be used for the research of moderate-to-severe plaque psoriasis and rheumatoid arthritis .
    Brodalumab
  • HY-120384
    AZD-0284
    2 Publications Verification

    		 ROR Inflammation/Immunology
    AZD-0284 is a selective inverse agonist of the nuclear receptor RORγ. AZD-0284 has the potential for plaque psoriasis vulgaris and respiratory tract disorders treatment .
    AZD-0284
  • HY-P9924
    Ixekizumab

    LY2439821

    		 Interleukin Related Inflammation/Immunology
    Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A (KD<3 pM). Ixekizumab directly blocks IL-17A binding to IL-17RA (IL-17A receptor) but does not bind to other IL-17 family members. Ixekizumab is used for the research of moderate-to-severe plaque psoriasis .
    Ixekizumab
  • HY-151363
    IRAK4-IN-21

    		IRAK Inflammation/Immunology
    IRAK4-IN-21 (compound 17) is an orally active, potent and selective IRAK4 inhibitor with IC50 values of 5 and 56 nM for IRAK4 and TAK1, respectively. IRAK4-IN-21 effectively inhibits IL-23 production (IC50=0.17 µM) and can be used in studies of autoimmune diseases such as plaque psoriasis and psoriatic arthritis .
    IRAK4-IN-21
  • HY-151365
    IRAK4-IN-22

    		IRAK Inflammation/Immunology
    IRAK4-IN-22 (compound 18) is an orally active, potent and selective IRAK4 inhibitor with IC50 values of 3 and 17 nM for IRAK4 and TAK1, respectively. IRAK4-IN-21 effectively inhibits IL-23 production (IC50=0.10 µM) and can be used in studies of autoimmune diseases such as plaque psoriasis and psoriatic arthritis .
    IRAK4-IN-22
  • HY-P9947
    Efalizumab

    		Integrin Others
    Efalizumab is a targeted T cell modulator, and is a humanized monoclonal antibody of CD11a, the α subunit of LFA-1. Efalizumab inhibits T cell activation, cutaneous T cell trafficking, and T cell adhesion to keratinocytes, can be used for plaque psoriasis research .
    Efalizumab
  • HY-P99754
    Netakimab

    		Interleukin Related Inflammation/Immunology
    Netakimab is an anti-IL-17 monoclonal antibody. Nerelimomab can be used for research of ankylosing spondylitis, psoriatic arthritis, moderate-to-severe plaque psoriasis .
    Netakimab
  • HY-144683
    PF-07038124

    		Phosphodiesterase (PDE) Inflammation/Immunology
    PF-07038124 is a PDE4 inhibitor with an IC50 of 0.5 nM for PDE4B2. PF-07038124 shows inhibitory activities against IL-13, IL4, and IFNγ (IC50=125, 4.1, 1.06 nM, respectively). PF-07038124 can be used for research of atopic dermatitis and plaque psoriasis .
    PF-07038124
  • HY-144683A
    PF-07038124 hydrochloride

    		Phosphodiesterase (PDE) Inflammation/Immunology
    PF-07038124 hydrochloride is a PDE4 inhibitor with an IC50 of 0.5 nM for PDE4B2. PF-07038124 hydrochloride shows inhibitory activities against IL-13, IL4, and IFNγ (IC50=125, 4.1, 1.06 nM, respectively). PF-07038124 hydrochloride can be used for research of atopic dermatitis and plaque psoriasis .
    PF-07038124 hydrochloride
  • HY-158159
    IL17A-IN-1

    		Interleukin Related Inflammation/Immunology Cancer
    IL17A-IN-1 (compound 72) is an orally active Interleukin 17A inhibitor. IL17A-IN-1 can be used in the study of inflammatory and autoimmune diseases (plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis, etc.), as well as cancer .
    IL17A-IN-1
  • HY-15388S
    Tazarotene-d8

    AGN 190168-d8

    		 Isotope-Labeled Compounds RAR/RXR Autophagy Inflammation/Immunology Cancer
    Tazarotene-d8 is the deuterium labeled Tazarotene. Tazarotene (AGN 190168) is a selective retinoic acid receptor (RAR) agonist for the treatment of plaque psoriasis and acne vulgaris[1][2].
    Tazarotene-d8
  • HY-109105
    Tepilamide fumarate

    XP-23829; PPC-06

    		 Others Inflammation/Immunology
    Tepilamide fumarate (XP-23829; PPC-06) is an oral fumaric acid ester, acts as a proagent of Monomethyl fumarate (HY-103252), and is used in the research of moderate to severe chronic plaque psoriasis. Tepilamide fumarate can enhance the effectiveness of oncolytic viruses .
    Tepilamide fumarate
  • HY-15388
    Tazarotene
    2 Publications Verification

    AGN 190168

    		 RAR/RXR Autophagy Inflammation/Immunology Cancer
    Tazarotene (AGN 190168) is a selective retinoic acid receptor (RAR) agonist for the treatment of plaque psoriasis and acne vulgaris. Tazarotene is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Tazarotene
  • HY-P9927
    Secukinumab
    1 Publications Verification

    AIN457

    		 Interleukin Related Inflammation/Immunology Cancer
    Secukinumab (AIN457) is a high affinity, human monoclonal antibody targeted against interleukin (IL)-17A. Secukinumab is the first-in-class anti-IL-17 agent used for the research of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis .
    Secukinumab
  • HY-16755
    Solcitinib

    GSK-2586184; GLPG-0778

    		 JAK Inflammation/Immunology
    Solcitinib is an orally active, competitive, potent, selective JAK1 inhibitor, with an IC50 of 9.8 nM, and 11-, 55- and 23-fold selectivity over JAK2, JAK3 and TYK2, respectively; Solcitinib is used in the research of moderate-to-severe plaque-type psoriasis.
    Solcitinib
  • HY-108847
    Etanercept
    5+ Cited Publications

    		 TNF Receptor Bacterial Inflammation/Immunology Cancer
    Etanercept, a dimeric fusion protein that binds TNF, acts as a TNF inhibitor. Etanercept competitively inhibits the binding of both TNF-α and TNF-β to cell surface TNF receptors, rendering TNF biologically inactive. Etanercept shows efficacy against rheumatoid arthritis, juvenile idiopathic arthritis, and plaque psoriasis .
    Etanercept
  • HY-15388R
    Tazarotene (Standard)

    		RAR/RXR Autophagy Inflammation/Immunology Cancer
    Tazarotene (Standard) is the analytical standard of Tazarotene. This product is intended for research and analytical applications. Tazarotene (AGN 190168) is a selective retinoic acid receptor (RAR) agonist for the treatment of plaque psoriasis and acne vulgaris. Tazarotene is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Tazarotene (Standard)
  • HY-P99256
    Tildrakizumab

    SCH 900222; MK 3222; Anti-Human IL23 Recombinant Antibody

    		 Interleukin Related Inflammation/Immunology Cancer
    Tildrakizumab (SCH 900222) is a humanized anti-IL-23 (p19 subunit) monoclonal antibody. IL-23 is a critical cytokine to maintain the Th17 cell phenotype. Tildrakizumab has high-affinity for single-chain IL-23 (Kd: 136 pM). Tildrakizumab is effective against moderate to severe plaque psoriasis .
    Tildrakizumab
  • HY-160144S
    Lomedeucitinib

    BMS-986322

    		 Isotope-Labeled Compounds JAK IFNAR Inflammation/Immunology
    Lomedeucitinib (BMS-986322) is a tyrosine protein kinase (TYK2) inhibitor. Lomedeucitinib has anti-inflammatory activity and significant inhibitory effect on IFNα (IC50=0.047 μM) production downstream of IL-12/TYK2. Lomedeucitinib is indicated for the study of plaque psoriasis and pruritus .
    Lomedeucitinib
  • HY-117287A
    Deucravacitinib hydrochloride

    BMS-986165 hydrochloride

    		 Interleukin Related JAK IFNAR Inflammation/Immunology
    Deucravacitinib hydrochloride (BMS-986165 hydrochloride) is a highly selective all-site inhibitor with potent inhibitory activity against TYK2. Deucravacitinib hydrochloride can effectively block IL-12, IL-23 and type I interferon signaling. Deucravacitinib hydrochloride demonstrates significant efficacy in preclinical models of inflammatory bowel disease. Deucravacitinib hydrochloride demonstrated superiority over placebo and apremilast on multiple efficacy endpoints in moderate to severe plaque psoriasis. Deucravacitinib hydrochloride was well tolerated in inhibition .
    Deucravacitinib hydrochloride
  • HY-P99940
    Remtolumab

    ABT-122

    		 TNF Receptor Interleukin Related Inflammation/Immunology
    Remtolumab (ABT-122) is a dual-variable domain immunoglobulin that neutralises both tumor necrosis factor α (TNFα) and IL-17A. Remtolumab shows dual inhibition of TNFα and IL-17A. Remtolumab can be used for rheumatoid arthritis (RA) research .
    Remtolumab
  • HY-117287
    Deucravacitinib
    Maximum Cited Publications
    16 Publications Verification

    BMS-986165

    		 JAK Interleukin Related IFNAR Inflammation/Immunology
    Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable allosteric TYK2 inhibitor for the treatment of autoimmune diseases, which selectively binds to TYK2 pseudokinase (JH2) domain (IC50=1.0 nM) and blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain. Deucravacitinib inhibits IL-12/23 and type I IFN pathways. Deucravacitinib, the FDA's world first de novo deuterium, is available for study in moderate to severe plaque psoriasis .
    Deucravacitinib
  • HY-15388S1
    Tazarotene-13C2,d2

    AGN 190168-13C2,d2

    		 Isotope-Labeled Compounds Inflammation/Immunology Cancer
    Tazarotene-13C2,d2 (AGN 190168-13C2,d2) is the 13C and deuterium labeled isotope of Tazarotene (HY-15388). Tazarotene (AGN 190168) is a selective retinoic acid receptor (RAR) agonist for the treatment of plaque psoriasis and acne vulgaris. Tazarotene is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups .
    Tazarotene-13C2,d2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: